Answers are grounded in this paper and cite their sources.
In vitro study demonstrates enhanced drug uptake and potency using dye-conjugated crizotinib in patient-derived glioblastoma cells, highlighting a promising delivery strategy across brain barriers.
Brain tumors, specifically high‐grade gliomas such as glioblastoma (GBM), are challenging to treat due to the presence of physiological barriers such as blood–brain barrier (BBB) and tumor heterogeneity. Designing drugs that address these brain tumor‐specific drug discovery challenges will herald much‐needed breakthroughs for this patient population. This study presents a proof of concept for the in vitro cellular activity of the multitargeted kinase inhibitor crizotinib conjugated to BBB‐crossing heptamethine cyanine dyes decorated with various functional groups in four patient‐derived GBM cell lines. We also present evidence of cellular uptake, which contributes to the observed improvement in potency of the conjugates.
No takes yet. Share an insight, caveat, or question.
Dumo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: